Half Year 2025 IXICO PLC Earnings Call Transcript
Key Points
- IXICO PLC (LSE:IXI) reported a 26% increase in revenue for the first half of 2025, driven by both long-term and short-term contracts.
- The company achieved a significant improvement in gross margin, increasing from 40% to 50% compared to the same period last year.
- IXICO PLC has successfully launched a next-generation version of its AI-driven platform, Trial Tracker, which is being deployed with new customers.
- The company has a strong cash position of GBP5 million and remains debt-free, allowing for strategic investments in innovation and commercial scaling.
- IXICO PLC has diversified its order book, with 17 clients and 25 different projects, providing a strong foundation for future revenue growth.
- The biotech sector continues to face macroeconomic challenges, impacting capital access for some clients.
- Despite revenue growth, IXICO PLC reported an EBITDA loss of GBP700,000 for the first half of the year.
- The company experienced client descopes or cancellations amounting to GBP2.9 million over the past 12 months.
- IXICO PLC's order book is heavily reliant on early-phase trials, which carry inherent risks if trials do not progress successfully.
- The company is still in the process of expanding its presence in the US market, where it faces competition from larger, established players.
Good afternoon and welcome to the IXICO PLC results investor presentation. (Operator Instructions) Before we begin, I'd like to submit the following poll. I'd now like to hand you to CEO, Bram Goorden. Good afternoon to you, sir.
Well, thank you very much and welcome everyone. I'm delighted to be presenting the H1 interim results for 2025, which are, as you may remember the first for me, and I started as CEO summer last year. Obviously, Grant is a somewhat more familiar face to you, I think, as our CFO and recently also promoted to Chief Operating Officer.
So with that, let's dive into this.
I wanted to remind everyone of who we are and what we do, just to make sure that we set the scene correctly. You see us actually using a somewhat different language maybe than what has been seen before. Precision in neuroscience because that is very much who we are. So we run an AI driven technology, a platform that does analytics of neurological clinical trials, and behind that is of course an entire team
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
